Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA known ✓ | P10253 | 3/20 | 0.40 |
| ▸ | CACNA1B known ✓ | Q00975 | 2/20 | 0.39 |
| ▸ | CHRM2 known ✓ | P08172 | 1/20 | 0.39 |
| ▸ | HTR1A known ✓ | P08908 | 1/20 | 0.39 |
| ▸ | ADRA2A known ✓ | P08913 | 1/20 | 0.39 |
| ▸ | MAOA known ✓ | P21397 | 1/20 | 0.39 |
| ▸ | DRD1 known ✓ | P21728 | 1/20 | 0.39 |
| ▸ | ACHE known ✓ | P22303 | 1/20 | 0.39 |
| ▸ | PTGS1 known ✓ | P23219 | 1/20 | 0.39 |
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.39 |
| ▸ | SLC6A4 known ✓ | P31645 | 1/20 | 0.39 |
| ▸ | OPRM1 known ✓ | P35372 | 1/20 | 0.39 |
| ▸ | DRD3 known ✓ | P35462 | 1/20 | 0.39 |
| ▸ | KDR known ✓ | P35968 | 1/20 | 0.39 |
| ▸ | SLC6A3 known ✓ | Q01959 | 1/20 | 0.39 |
| ▸ | KCNH2 known ✓ | Q12809 | 1/20 | 0.39 |
| ▸ | HRH3 known ✓ | Q9Y5N1 | 1/20 | 0.39 |
| ▸ | TERT | O14746 | 1/20 | 0.95 |
| ▸ | APAF1 | O14727 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL68756 | 1.00 | TERT (0.95) | TERTAPAF1CYP3A4TSHRMAPK1 | |
| SCHEMBL68757 | 0.98 | TERT (1.00) | TERTAPAF1CYP3A4TSHRMAPK1 | |
| SCHEMBL29522375 | 0.98 | TERT (1.00) | TERTAPAF1CYP3A4TSHRMAPK1 | |
| SCHEMBL22855832 | 0.93 | TERT (0.91) | TERTAPAF1CYP3A4TSHRMAPK1 | |
| Hydrochloric Acid SCHEMBL27085683 | 0.93 | TERT (0.91) | TERTAPAF1CYP3A4TSHRMAPK1 | |
| SCHEMBL20748333 | 0.87 | TERT (0.80) | TERTAPAF1CYP3A4TSHRMAPK1 | |
| SCHEMBL11702475 | 0.84 | TERT (0.74) | TERTAPAF1NPC1ALDH1A1RAB9A | |
| Hydrochloric Acid SCHEMBL29438188 | 0.82 | APAF1 (0.71) | TERTAPAF1CYP3A4MAPK1NPC1 | |
| SCHEMBL2466326 | 0.82 | TERT (0.73) | TERTAPAF1CYP3A4TSHRMAPK1 | |
| SCHEMBL31355408 | 0.82 | TERT (0.73) | TERTAPAF1CYP3A4TSHRMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4642492-A1 | AN ANTIBODY-DRUG CONJUGATE HAVING TWO OR MORE FUNCTIONAL SMALL MOLECULE COMPOUNDS FOR ENHANCED TREATMENT OF REFRACTORY DISEASES | Hangzhou Seehe Biotechnology Co., Ltd (CN) | 2025-11-05 | — | — | EP | claimed |
| WO-2024240173-A1 | AN ANTIBODY-DRUG CONJUGATE HAVING TWO OR MORE FUNCTIONAL SMALL MOLECULE COMPOUNDS FOR ENHANCED TREATMENT OF REFRACTORY DISEASES | HANGZHOU SEEHE BIOTECHNOLOGY CO., LTD (CN) | 2024-11-28 | — | — | WO | claimed |
| EP-4314334-A1 | CAPTURE CONSTRUCT AND METHOD FOR DETECTING A PLURALITY OF ANALYTES | Leica Microsystems CMS GmbH (DE) | 2024-02-07 | — | — | EP | disclosed |
| CN-116802050-A | Decorative panel and decorative floor covering consisting of said panel | I4F许可有限责任公司 | 2023-09-22 | — | — | CN | disclosed |
| US-11473129-B2 | Multiplex labeling of molecules by sequential hybridization barcoding | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2022-10-18 | — | — | US | disclosed |
| WO-2022207832-A1 | CAPTURE CONSTRUCT AND METHOD FOR DETECTING A PLURALITY OF ANALYTES | LEICA MICROSYSTEMS CMS GMBH (DE) | 2022-10-06 | — | — | WO | disclosed |
| US-10589003-B2 | Methods for coating surfaces with antimicrobial agents | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2020-03-17 | — | — | US | disclosed |
| US-20180303977-A1 | METHODS FOR COATING SURFACES WITH ANTIMICROBIAL AGENTS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2018-10-25 | — | — | US | disclosed |
| US-20120039813-A1 | INTRINSICALLY COLORED, LUMINESCENT SILK FIBROIN AND A METHOD OF PRODUCING THE SAME | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2012-02-16 | — | — | US | disclosed |
| WO-2010096025-A1 | INTRINSICALLY COLORED, LUMINESCENT SILK FIBROIN AND A METHOD OF PRODUCING THE SAME | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2010-08-26 | — | — | WO | disclosed |
| US-20100119709-A1 | Organic colorants and compositions containing same | RAGAN SEAN MICHAEL | 2010-05-13 | — | — | US | disclosed |
| US-20030152019-A1 | Limited play optical devices with interstitial reactive layer and methods of making same | FLEXPLAY TECHNOLOGIES, INC. | 2003-08-14 | — | — | US | disclosed |
| US-20030129408-A1 | Limited play optical devices with interstitial reactive layer and methods of making same | FLEXPLAY TECHNOLOGIES, INC. | 2003-07-10 | — | — | US | disclosed |
| US-20030123379-A1 | Limited play optical devices with interstitial reactive layer and methods of making same | FLEXPLAY TECHNOLOGIES, INC. | 2003-07-03 | — | — | US | disclosed |
| US-20030123302-A1 | Limited play optical devices with interstitial reactive layer and methods of making same | FLEXPLAY TECHNOLOGIES, INC. | 2003-07-03 | — | — | US | disclosed |
| US-20030112737-A1 | Limited play optical devices with interstitial reactive layer and methods of making same | FLEXPLAY TECHNOLOGIES, INC. | 2003-06-19 | — | — | US | disclosed |
| WO-2002099470-A2 | LIMITED PLAY OPTICAL DEVICES WITH INTERSTITIAL REACTIVE LAYER AND METHODS OF MAKING SAME | FLEXPLAY TECHNOLOGIES, INC. (US) | 2002-12-12 | — | — | WO | disclosed |
| US-5652093-A | Analogues of reporter groups as background reducers in binding assays | APROGENEX, INC. (US) | 1997-07-29 | — | — | US | disclosed |
| US-5501952-A | Analogues of reporter groups as background reducers in hybridization assays | APROGENEX, INC. (US) | 1996-03-26 | — | — | US | disclosed |
| WO-1995002699-A1 | ANALOGUES OF REPORTER GROUPS AS BACKGROUNG REDUCERS IN HYBRIDIZATION ASSAYS | APROGENEX, INC. (US) | 1995-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10589003-B2 | Methods for coating surfaces with antimicrobial agents | CUTA, CD63, CDC37 | GAA 2214/4885CACNA1B 4649/4885CHRM2 2903/4885 |
| US-20120039813-A1 | INTRINSICALLY COLORED, LUMINESCENT SILK FIBROIN AND A METHOD OF PRODUCING THE SAME | IK, FGB, VIP | GAA 2943/4885CACNA1B 3822/4885CHRM2 1897/4885 |
| US-20100119709-A1 | Organic colorants and compositions containing same | NOS2, NOS1, TYR | GAA 2241/4885CACNA1B 4734/4885CHRM2 555/4885 |
| US-20180303977-A1 | METHODS FOR COATING SURFACES WITH ANTIMICROBIAL AGENTS | CUTA, CD63, CDC37 | GAA 2214/4885CACNA1B 4649/4885CHRM2 2903/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.